{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:32:31Z","timestamp":1792290751323,"version":"4.4.0"},"reference-count":181,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>The peritoneum is a common site for the dissemination of digestive malignancies, particularly gastric, colorectal, appendix, or pancreatic cancer. Other tumors such as cholangiocarcinomas, digestive neuroendocrine tumors, or gastrointestinal stromal tumors (GIST) may also associate with peritoneal surface metastases (PSM). Peritoneal dissemination is proven to worsen the prognosis of these patients. Cytoreductive surgery (CRS), along with systemic chemotherapy, have been shown to constitute a survival benefit in selected patients with PSM. Furthermore, the association of CRS with hyperthermic intraperitoneal chemotherapy (HIPEC) seems to significantly improve the prognosis of patients with certain types of digestive malignancies associated with PSM. However, the benefit of CRS with HIPEC is still controversial, especially due to the significant morbidity associated with this procedure. According to the results of the PRODIGE 7 trial, CRS for PSM from colorectal cancer (CRC) achieved overall survival (OS) rates higher than 40 months, but the addition of oxaliplatin-based HIPEC failed to improve the long-term outcomes. Furthermore, the PROPHYLOCHIP and COLOPEC trials failed to demonstrate the effectiveness of oxaliplatin-based HIPEC for preventing peritoneal metastases development in high-risk patients operated for CRC. In this review, we discuss the limitations of these studies and the reasons why these results are not sufficient to refute this technique, until future well-designed trials evaluate the impact of different HIPEC regimens. In contrast, in pseudomyxoma peritonei, CRS plus HIPEC represents the gold standard therapy, which is able to achieve 10-year OS rates ranging between 70 and 80%. For patients with PSM from gastric carcinoma, CRS plus HIPEC achieved median OS rates higher than 40 months after complete cytoreduction in patients with a peritoneal cancer index (PCI) \u22646. However, the data have not yet been validated in randomized clinical trials. In this review, we discuss the controversies regarding the most efficient drugs that should be used for HIPEC and the duration of the procedure. We also discuss the current evidence and controversies related to the benefit of CRS (and HIPEC) in patients with PSM from other digestive malignancies. Although it is a palliative treatment, pressurized intraperitoneal aerosolized chemotherapy (PIPAC) significantly increases OS in patients with unresectable PSM from gastric cancer and represents a promising approach for patients with PSM from other digestive cancers.<\/jats:p>","DOI":"10.3390\/medicina59020255","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T04:58:25Z","timestamp":1675054705000},"page":"255","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Surgical Options for Peritoneal Surface Metastases from Digestive Malignancies\u2014A Comprehensive Review"],"prefix":"10.3390","volume":"59","author":[{"given":"Mihai Adrian","family":"Eftimie","sequence":"first","affiliation":[{"name":"Department of General Surgery, Fundeni Clinical Institute, 022328 Bucharest, Romania"},{"name":"Department of Surgery, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheorghe","family":"Potlog","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2783-2769","authenticated-orcid":false,"given":"Sorin Tiberiu","family":"Alexandrescu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Fundeni Clinical Institute, 022328 Bucharest, Romania"},{"name":"Department of Surgery, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,28]]},"reference":[{"key":"ref_1","first-page":"18","article-title":"Then and now: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective","volume":"7","author":"Neuwirth","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/DCR.0b013e3182a62d9d","article-title":"Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin","volume":"56","author":"Thomassen","year":"2013","journal-title":"Dis. Colon Rectum"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.3748\/wjg.v25.i27.3484","article-title":"Colorectal peritoneal metastases: Optimal management review","volume":"25","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","article-title":"Peritonectomy procedures","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann. Surg."},{"key":"ref_5","first-page":"2317","article-title":"Peritonectomy combined with intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: Phase I-II study","volume":"19","author":"Gilly","year":"1999","journal-title":"Anticancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jso.21061","article-title":"Hyperthermic intraperitoneal chemotherapy: Nomenclature and modalities of perfusion","volume":"98","author":"Glehen","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"ref_7","first-page":"431","article-title":"Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection","volume":"1","author":"Elias","year":"2000","journal-title":"Int. J. Surg. Investig."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"20190015","DOI":"10.1515\/pp-2019-0015","article-title":"Impact of extent of parietal peritonectomy on oncological outcome after cytoreductive surgery and HIPEC","volume":"4","author":"Somashekhar","year":"2019","journal-title":"Pleura Peritoneum"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3802\/jgo.2015.26.4.336","article-title":"Role of aggressive surgical cytoreduction in advanced ovarian cancer","volume":"26","author":"Chang","year":"2015","journal-title":"J. Gynecol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial","volume":"32","author":"Hilpert","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1007\/s00423-021-02353-z","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases: Analysis of short- and long-term outcomes","volume":"406","author":"Rosa","year":"2021","journal-title":"Langenbeck\u2019s Arch. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","article-title":"Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial","volume":"3","author":"Homann","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_14","first-page":"59","article-title":"Surgical biology for the clinician: Peritoneal mesothelioma: Current understanding and management","volume":"52","author":"Chua","year":"2009","journal-title":"Can. J. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","article-title":"Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: First evidence for efficacy","volume":"21","author":"Solass","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/SLA.0b013e3181a45d86","article-title":"Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: A systematic review of morbidity and mortality","volume":"249","author":"Chua","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/SLA.0000000000005101","article-title":"Half of Postoperative Deaths After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Could be Preventable: A French Root Cause Analysis on 5562 Patients","volume":"274","author":"Glehen","year":"2021","journal-title":"Ann. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.15403\/jgld-2688","article-title":"Influence of the Primary Tumor Location on the Pattern of Synchronous Metastatic Spread in Patients with Stage IV Colorectal Carcinoma, According to the 8 th Edition of the AJCC Staging System","volume":"29","author":"Alexandrescu","year":"2020","journal-title":"J. Gastrointestin Liver Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/bjs.8679","article-title":"Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer","volume":"99","author":"Segelman","year":"2012","journal-title":"Br. J. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/DCR.0000000000000412","article-title":"Epidemiology, Management, and Survival of Peritoneal Carcinomatosis from Colorectal Cancer: A Population-Based Study","volume":"58","author":"Quere","year":"2015","journal-title":"Dis. Colon Rectum"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1245\/s10434-012-2473-5","article-title":"Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: A systematic review","volume":"20","author":"Souadka","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_22","first-page":"1840","article-title":"Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug","volume":"44","author":"Koga","year":"1984","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study","volume":"28","author":"Elias","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/SLA.0b013e3182263933","article-title":"Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis","volume":"254","author":"Mehta","year":"2011","journal-title":"Ann. Surg."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/SLA.0b013e31827e9289","article-title":"Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy?","volume":"257","author":"Malka","year":"2013","journal-title":"Ann. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Elias","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","article-title":"Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study","volume":"22","author":"Glehen","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1245\/s10434-013-3061-z","article-title":"Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States","volume":"21","author":"Turaga","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.ejso.2006.06.007","article-title":"Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma: Non-mucinous tumour associated with an improved survival","volume":"32","author":"Yan","year":"2006","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jamcollsurg.2006.08.024","article-title":"Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer","volume":"203","author":"Sugarbaker","year":"2006","journal-title":"J. Am. Coll. Surg."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejso.2010.10.014","article-title":"Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O","volume":"37","author":"Cavaliere","year":"2011","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.surg.2012.07.027","article-title":"Predictors of survival in patients with high-grade peritoneal metastases undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"152","author":"Hanseman","year":"2012","journal-title":"Surgery"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4251\/wjgo.v2.i1.31","article-title":"Selection of patients and staging of peritoneal surface malignancies","volume":"2","author":"Cotte","year":"2010","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"978394","DOI":"10.1155\/2013\/978394","article-title":"Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy","volume":"2013","author":"Yonemura","year":"2013","journal-title":"Sci. World J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1477-7819-10-56","article-title":"Small bowel involvement is a prognostic factor in colorectal carcinomatosis treated with complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy","volume":"10","author":"Benizri","year":"2012","journal-title":"World J. Surg. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ejso.2014.06.006","article-title":"Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin","volume":"40","author":"Elias","year":"2014","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1007\/s12094-018-1857-9","article-title":"Peritoneal carcinomatosis arising from rectal or colonic adenocarcinoma treated with cytoreductive surgery (CRS) hyperthermic intraperitoneal chemotherapy (HIPEC): Two different diseases","volume":"20","author":"Tonello","year":"2018","journal-title":"Clin. Transl. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.surg.2018.07.027","article-title":"The location of the primary colon cancer has no impact on outcomes in patients undergoing cytoreductive surgery for peritoneal metastasis","volume":"165","author":"Mercier","year":"2019","journal-title":"Surgery"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.amjsurg.2016.03.008","article-title":"Peritoneal carcinomatosis of colorectal cancer: Novel clinical and molecular outcomes","volume":"213","author":"Massalou","year":"2017","journal-title":"Am. J. Surg."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/apt.17045","article-title":"Review article: Obesity and colorectal cancer","volume":"56","author":"Bardou","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/SLA.0b013e31819eda21","article-title":"Effect of subjective preoperative variables on risk-adjusted assessment of hospital morbidity and mortality","volume":"249","author":"Cohen","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e186847","DOI":"10.1001\/jamanetworkopen.2018.6847","article-title":"Morbidity and Mortality Rates Following Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy Compared with Other High-Risk Surgical Oncology Procedures","volume":"2","author":"Foster","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.21037\/jgo-2020-05","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases: Lessons learned from PRODIGE 7","volume":"12","author":"Cashin","year":"2021","journal-title":"J. Gastrointest Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/CAD.0b013e3282f07791","article-title":"Exposure-response relationships for oxaliplatin-treated colon cancer cells","volume":"19","author":"Kirstein","year":"2008","journal-title":"Anticancer Drugs"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/jso.25437","article-title":"Body surface area-based vs concentration-based perioperative intraperitoneal chemotherapy after optimal cytoreductive surgery in colorectal peritoneal surface malignancy treatment: COBOX trial","volume":"119","author":"Lemoine","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jamcollsurg.2013.12.013","article-title":"Intraperitoneal chemotherapy for peritoneal surface malignancy: Experience with 1000 patients","volume":"218","author":"Levine","year":"2014","journal-title":"J. Am. Coll. Surg."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Yurttas, C., Hoffmann, G., Tolios, A., Haen, S.P., Schwab, M., K\u00f6nigsrainer, I., K\u00f6nigsrainer, A., Beckert, S., and L\u00f6ffler, M.W. (2018). Systematic Review of Variations in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis from Colorectal Cancer. J. Clin. Med., 7.","DOI":"10.3390\/jcm7120567"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/jso.23546","article-title":"The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative study","volume":"109","author":"Hompes","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/jso.23722","article-title":"The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery","volume":"110","author":"Esquivel","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejso.2016.09.015","article-title":"Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis","volume":"43","author":"Leung","year":"2017","journal-title":"Eur. J. Surg. Oncol"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/SLA.0b013e31826b4dcc","article-title":"Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases","volume":"256","author":"Andreou","year":"2012","journal-title":"Ann. Surg."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"Figer","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1245\/s10434-020-08482-x","article-title":"Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Not Associated with Prohibitive Complications: Results of a Multiinstitutional Retrospective Study","volume":"27","author":"Powers","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/jso.23062","article-title":"Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: Postoperative and long-term results","volume":"106","author":"Golse","year":"2012","journal-title":"J. Surg. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/jso.21084","article-title":"Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms","volume":"98","author":"Bijelic","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"795390","DOI":"10.3389\/fonc.2021.795390","article-title":"Effect of HIPEC on Peritoneal Recurrence in Peritoneal Metastasis Treated with Cytoreductive Surgery: A Systematic Review","volume":"11","author":"Yap","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_59","first-page":"99","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A review of factors contributing to morbidity and mortality","volume":"7","author":"Newton","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/SLA.0b013e31822638f6","article-title":"Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis","volume":"254","author":"Elias","year":"2011","journal-title":"Ann. Surg."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/SLA.0b013e31815f0113","article-title":"Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis","volume":"247","author":"Elias","year":"2008","journal-title":"Ann. Surg."},{"key":"ref_62","first-page":"96","article-title":"Systematic Second-Look Surgery Plus HIPEC in Patients without Evidence of Recurrence, at High Risk of Carcinomatosis after Colorectal Cancer Resection","volume":"96","author":"Viejo","year":"2018","journal-title":"Cir. Esp."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00384-014-1929-4","article-title":"Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases","volume":"29","author":"Sammartino","year":"2014","journal-title":"Int. J. Color. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"506571","DOI":"10.1155\/2012\/506571","article-title":"Preliminary results of hyperthermic intraperitoneal intraoperative chemotherapy as an adjuvant in resectable pancreatic cancer","volume":"2012","author":"Tentes","year":"2012","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1245\/s10434-016-5488-5","article-title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases","volume":"24","author":"Baratti","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/bjc.2014.369","article-title":"Intraperitoneal chemotherapy as adjuvant treatment to prevent peritoneal carcinomatosis of colorectal cancer origin: A systematic review","volume":"111","author":"Sloothaak","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(20)30322-3","article-title":"Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): A randomised, phase 3 study","volume":"21","author":"Glehen","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): A multicentre, open-label, randomised trial","volume":"4","author":"Klaver","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Sommariva, A., Tonello, M., Coccolini, F., De Manzoni, G., Delrio, P., Pizzolato, E., Gelmini, R., Serra, F., Rreka, E., and Pasqual, E.M. (2022). Colorectal Cancer with Peritoneal Metastases: The Impact of the Results of PROPHYLOCHIP, COLOPEC, and PRODIGE 7 Trials on Peritoneal Disease Management. Cancers, 15.","DOI":"10.3390\/cancers15010165"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/bjs.5513","article-title":"Surgical strategies for gastric cancer with synchronous peritoneal carcinomatosis","volume":"93","author":"Gretschel","year":"2006","journal-title":"Br. J. Surg."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.ejso.2013.10.010","article-title":"Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Overview and rationale","volume":"39","author":"Roviello","year":"2013","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"531","DOI":"10.6004\/jnccn.2013.0070","article-title":"Gastric cancer, version 2.2013: Featured updates to the NCCN Guidelines","volume":"11","author":"Ajani","year":"2013","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S1470-2045(18)30791-5","article-title":"Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Fuchs","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/(SICI)1097-0142(19970301)79:5<884::AID-CNCR3>3.0.CO;2-C","article-title":"Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery","volume":"79","author":"Fujimoto","year":"1997","journal-title":"Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0039-6060(96)80145-0","article-title":"Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination","volume":"119","author":"Yonemura","year":"1996","journal-title":"Surgery"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/archsurg.139.1.20","article-title":"Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer","volume":"139","author":"Glehen","year":"2004","journal-title":"Arch. Surg."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","article-title":"Peritoneal carcinomatosis from gastric cancer: A multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy","volume":"17","author":"Glehen","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4251\/wjgo.v2.i2.85","article-title":"Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer","volume":"2","author":"Yonemura","year":"2010","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.18.01688","article-title":"Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis","volume":"37","author":"Bonnot","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.ejso.2015.03.231","article-title":"Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis","volume":"41","author":"Coccolini","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1245\/s10434-013-3443-2","article-title":"Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan","volume":"21","author":"Canbay","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"9060","DOI":"10.1245\/s10434-021-10157-0","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Synchronous Peritoneal Metastases: Multicenter Study of \u2019Italian Peritoneal Surface Malignancies Oncoteam-S.I.C.O","volume":"28","author":"Marano","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.ejso.2018.06.036","article-title":"Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis","volume":"44","author":"Caro","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1002\/cam4.2204","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) in combined treatment of locally advanced and intraperitonealy disseminated gastric cancer: A retrospective cooperative Central-Eastern European study","volume":"8","author":"Yarema","year":"2019","journal-title":"Cancer Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10120-019-00978-0","article-title":"Peritoneal metastasis in gastric cancer: Results from the German database","volume":"23","author":"Rau","year":"2020","journal-title":"Gastric Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1007\/s10120-019-00969-1","article-title":"The efficacy of treatment options for patients with gastric cancer and peritoneal metastasis","volume":"22","author":"Rau","year":"2019","journal-title":"Gastric Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1002\/cncr.25356","article-title":"Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: A multi-institutional study of 1290 patients","volume":"116","author":"Glehen","year":"2010","journal-title":"Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"9071","DOI":"10.1245\/s10434-021-10206-8","article-title":"ASO Author Reflections: Gastric Cancer with Synchronous Peritoneal Disease\u2014A Clinically Meaningful Survival after CRS and HIPEC in Selected Patients from Italian Peritoneal Surface Malignancies Oncoteam Network","volume":"28","author":"Marano","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5230\/jgc.2014.14.2.117","article-title":"Initial clinical experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in signet-ring cell gastric cancer with peritoneal metastases","volume":"14","author":"Horvath","year":"2014","journal-title":"J. Gastric Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/jso.25379","article-title":"Signet ring cell features with peritoneal carcinomatosis in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are associated with poor overall survival","volume":"119","author":"Solomon","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/bjs.10221","article-title":"Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer","volume":"103","author":"Hartwig","year":"2016","journal-title":"Br. J. Surg."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12885-019-5640-2","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II)","volume":"19","author":"Koemans","year":"2019","journal-title":"BMC Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00428-015-1734-7","article-title":"Changes in autopsy rates among cancer patients and their impact on cancer statistics from a public health point of view: A longitudinal study from 1980 to 2010 with data from Cancer Registry Zurich","volume":"466","author":"Bieri","year":"2015","journal-title":"Virchows Arch."},{"key":"ref_94","first-page":"689","article-title":"Feasibility of intraperitoneal Trastuzumab treatment in a patient with peritoneal carcinomatosis from gastric cancer","volume":"18","author":"Berretta","year":"2014","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Seyfried, F., von Rahden, B.H., Miras, A.D., Gasser, M., Maeder, U., Kunzmann, V., Germer, C.-T., Pelz, J., and Kerscher, A.G. (2015). Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin-a longitudinal experience from a prospectively collected database of 1108 patients. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1081-8"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0002-9610(99)00162-2","article-title":"Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma","volume":"178","author":"Bando","year":"1999","journal-title":"Am. J. Surg."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00000658-199307000-00008","article-title":"Comparison of survival curves of gastric cancer patients after surgery according to the UICC stage classification and the General Rules for Gastric Cancer Study by the Japanese Research Society for gastric cancer","volume":"218","author":"Nio","year":"1993","journal-title":"Ann. Surg."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/1471-2407-12-526","article-title":"Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: A meta-analysis of the randomized controlled trials","volume":"12","author":"Sun","year":"2012","journal-title":"BMC Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Beeharry, M.K., Zhu, Z.-L., Liu, W.-T., Yao, X.-X., Yan, M., and Zhu, Z.-G. (2019). Correction to: Prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: Personal experience from a randomized case control study. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6411-9"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Glehen, O., Passot, G., Villeneuve, L., Vaudoyer, D., Bin-Dorel, S., Boschetti, G., Piaton, E., and Garofalo, A. (2014). GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: A randomized and multicenter phase III study. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-183"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejso.2020.02.012","article-title":"Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI\/EURACAN clinical practice guidelines for diagnosis and treatment","volume":"47","author":"Govaerts","year":"2011","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/jso.21053","article-title":"Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination","volume":"98","author":"Esquivel","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1245\/s10434-014-4186-4","article-title":"A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion","volume":"22","author":"Ding","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1245\/s10434-014-3976-z","article-title":"Impact of distal pancreatectomy on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"22","author":"Doud","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1245\/s10434-016-5389-7","article-title":"Advanced Pseudomyxoma Peritonei Requiring Gastrectomy to Achieve Complete Cytoreduction Results in Good Long-Term Oncologic Outcomes","volume":"23","author":"Mehta","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"20180101","DOI":"10.1515\/pp-2018-0101","article-title":"The concept of \u2018Obstruction-Free Survival\u2019 as an outcome measure in advanced colorectal cancer management","volume":"3","author":"Moran","year":"2018","journal-title":"Pleura Peritoneum"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: Multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1245\/s10434-015-5019-9","article-title":"Can a Benefit be Expected from Surgical Debulking of Unresectable Pseudomyxoma Peritonei?","volume":"23","author":"Delhorme","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/01.sla.0000133183.15705.71","article-title":"Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy","volume":"240","author":"Glehen","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2214\/AJR.07.2018","article-title":"Mucinous appendiceal neoplasms: Preoperative MR staging and classification compared with surgical and histopathologic findings","volume":"190","author":"Low","year":"2008","journal-title":"Am. J. Roentgenol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0399-8320(05)88175-8","article-title":"Preoperative criteria of incomplete resectability of peritoneal carcinomatosis from non-appendiceal colorectal carcinoma","volume":"29","author":"Elias","year":"2005","journal-title":"Gastroenterol. Clin. Biol."},{"key":"ref_113","first-page":"563","article-title":"Free intraperitoneal tumors cells in pancreatic cancer-significance for clinical course and therapy","volume":"63","author":"Heeckt","year":"1992","journal-title":"Der Chir."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00534-007-1209-6","article-title":"Prognostic factors for long-term survival in patients with locally invasive pancreatic cancer","volume":"14","author":"Tani","year":"2007","journal-title":"J. Hepatobiliary Pancreat. Surg."},{"key":"ref_115","first-page":"482","article-title":"Cytoreduction and HIPEC for peritoneal carcinomatosis of pancreatic cancer","volume":"23","author":"Tentes","year":"2018","journal-title":"J. BUON"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/02656736.2016.1227094","article-title":"The effect of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) as an adjuvant in patients with resectable pancreatic cancer","volume":"32","author":"Tentes","year":"2016","journal-title":"Int. J. Hyperth."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3892\/ol.2021.12507","article-title":"Place of hyperthermic intraperitoneal chemotherapy in the armament against pancreatic adenocarcinoma: A survival, mortality and morbidity systematic review","volume":"21","author":"Larentzakis","year":"2021","journal-title":"Oncol. Lett."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.ejso.2018.04.023","article-title":"Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups","volume":"44","author":"Amblard","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.hoc.2008.11.006","article-title":"Gastrointestinal stromal tumor: A clinical overview","volume":"23","author":"Quek","year":"2009","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1477-7819-10-111","article-title":"Surgery after treatment with imatinib and\/or sunitinib in patients with metastasized gastrointestinal stromal tumors: Is it worthwhile?","volume":"10","author":"Tielen","year":"2012","journal-title":"World J. Surg. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11864-015-0384-y","article-title":"The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors","volume":"17","author":"Keung","year":"2016","journal-title":"Curr. Treat Options Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1200\/JCO.2005.11.601","article-title":"Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study","volume":"23","author":"Verweij","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"GSTMA Group (2010). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: A meta-analysis of 1640 patients. J. Clin. Oncol., 28, 1247\u20131253.","DOI":"10.1200\/JCO.2009.24.2099"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1245\/s10434-013-3279-9","article-title":"The effects of surgical cytoreduction prior to imatinib therapy on the prognosis of patients with advanced GIST","volume":"20","author":"An","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1245\/s10434-006-9047-3","article-title":"Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era","volume":"13","author":"Bonvalot","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2005.05.3439","article-title":"Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors","volume":"24","author":"Raut","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1245\/s10434-006-9034-8","article-title":"Surgical resection of gastrointestinal stromal tumors after treatment with imatinib","volume":"14","author":"Andtbacka","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/01.sla.0000236630.93587.59","article-title":"Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor","volume":"245","author":"DeMatteo","year":"2007","journal-title":"Ann. Surg."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/01.sla.0000242710.36384.1b","article-title":"Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced\/metastatic GIST","volume":"245","author":"Gronchi","year":"2007","journal-title":"Ann. Surg."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jamcollsurg.2014.02.037","article-title":"Surgical management of advanced gastrointestinal stromal tumors: An international multi-institutional analysis of 158 patients","volume":"219","author":"Bischof","year":"2014","journal-title":"J. Am. Coll. Surg."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1245\/s10434-014-4360-8","article-title":"Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: A retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS)","volume":"22","author":"Calabuig","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/annonc\/mdp310","article-title":"Post-imatinib surgery in advanced\/metastatic GIST: Is it worthwhile in all patients?","volume":"21","author":"Mussi","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jso.21065","article-title":"Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs)","volume":"98","author":"Sym","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijsu.2017.01.045","article-title":"Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: A prospective cohort study","volume":"39","author":"Yeh","year":"2017","journal-title":"Int. J. Surg."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1245\/s10434-009-0784-y","article-title":"Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate","volume":"17","author":"Raut","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_136","first-page":"840","article-title":"Significance of surgical treatment for recurrent and metastatic gastrointestinal stromal tumors","volume":"23","author":"Zhang","year":"2020","journal-title":"Chin. J. Gastrointest. Surg."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1080\/02656736.2017.1301576","article-title":"Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: Results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI)","volume":"33","author":"Passot","year":"2017","journal-title":"Int. J. Hyperth."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.ejso.2005.04.010","article-title":"Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis","volume":"31","author":"Bonvalot","year":"2005","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1245\/s10434-010-1178-x","article-title":"Peritoneal sarcomatosis: Is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?","volume":"17","author":"Baratti","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000286700","article-title":"ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors","volume":"91","author":"Kianmanesh","year":"2010","journal-title":"Neuroendocrinology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000371817","article-title":"Updating the surgical management of peritoneal carcinomatosis in patients with neuroendocrine tumors","volume":"101","author":"Brixi","year":"2015","journal-title":"Neuroendocrinology"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/jso.24727","article-title":"The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis","volume":"116","author":"Ejaz","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000096053","article-title":"Endocrine tumors of the ileum: Factors correlated with survival","volume":"83","author":"Tomassetti","year":"2006","journal-title":"Neuroendocrinology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/cncr.32865","article-title":"The Chicago Consensus on peritoneal surface malignancies: Management of neuroendocrine tumors","volume":"126","author":"Group","year":"2020","journal-title":"Cancer"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1245\/s10434-020-08321-z","article-title":"The Chicago Consensus on Peritoneal Surface Malignancies: Management of Neuroendocrine Tumors","volume":"27","author":"Group","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1159\/000509220","article-title":"Long-Term Results after Surgical Resection of Peritoneal Metastasis from Neuroendocrine Tumors","volume":"111","author":"Benhaim","year":"2021","journal-title":"Neuroendocrinology"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.surg.2013.05.030","article-title":"Neuroendocrine carcinomas: Optimal surgery of peritoneal metastases (and associated intra-abdominal metastases)","volume":"155","author":"Elias","year":"2014","journal-title":"Surgery"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.surg.2020.03.030","article-title":"Outcomes of cytoreductive operations for peritoneal carcinomatosis with or without liver cytoreduction in patients with small bowel neuroendocrine tumors","volume":"169","author":"Wonn","year":"2021","journal-title":"Surgery"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1245\/s10434-018-6433-6","article-title":"Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases","volume":"25","author":"Chan","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","article-title":"Surgical treatment of neuroendocrine metastases to the liver: A plea for resection to increase survival","volume":"197","author":"Sarmiento","year":"2003","journal-title":"J. Am. Coll. Surg."},{"key":"ref_151","unstructured":"Wind, G.G. (1997). Applied Laparoscopic Anatomy: Abdomen and Pelvis, Lippincott Williams & Wilkins. [1st ed.]."},{"key":"ref_152","first-page":"1091","article-title":"Cytoreductive hepatic surgery for neuroendocrine tumors","volume":"108","author":"McEntee","year":"1990","journal-title":"Surgery"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jamcollsurg.2016.12.032","article-title":"Aggressive Surgical Approach to the Management of Neuroendocrine Tumors: A Report of 1000 Surgical Cytoreductions by a Single Institution","volume":"224","author":"Woltering","year":"2017","journal-title":"J. Am. Coll. Surg."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.surg.2015.05.040","article-title":"Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?","volume":"159","author":"Maxwell","year":"2016","journal-title":"Surgery"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Bhatt, A. (2018). Management of Peritoneal Metastases-Cytoreductive Surgery, HIPEC and beyond, Springer.","DOI":"10.1007\/978-981-10-7053-2"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/SLA.0b013e31818e4641","article-title":"Small bowel cancer in the United States: Changes in epidemiology, treatment, and survival over the last 20 years","volume":"249","author":"Bilimoria","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archsurg.137.5.564","article-title":"Primary cancers of the small bowel: Analysis of prognostic factors and results of surgical management","volume":"137","author":"Talamonti","year":"2002","journal-title":"Arch. Surg."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1245\/s10434-011-2173-6","article-title":"A population-based comparison of adenocarcinoma of the large and small intestine: Insights into a rare disease","volume":"19","author":"Overman","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejca.2017.10.012","article-title":"Synchronous peritoneal metastases of small bowel adenocarcinoma: Insights into an underexposed clinical phenomenon","volume":"87","author":"Simkens","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/cncr.20404","article-title":"Adenocarcinoma of the small bowel: Presentation, prognostic factors, and outcome of 217 patients","volume":"101","author":"Dabaja","year":"2004","journal-title":"Cancer"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1080\/0284186X.2016.1182211","article-title":"Trends in incidence, treatment and survival of small bowel adenocarcinomas between 1999 and 2013: A population-based study in The Netherlands","volume":"55","author":"Bernards","year":"2016","journal-title":"Acta Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1245\/s10434-015-5056-4","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Dissemination from Small Bowel Malignancy: Results from a Single Specialized Center","volume":"23","author":"Liu","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2693::AID-CNCR14>3.0.CO;2-U","article-title":"The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: Review of the National Cancer Data Base, 1985\u20131995","volume":"86","author":"Howe","year":"1999","journal-title":"Cancer"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/BF02303567","article-title":"Small bowel cancer: A 30-year review","volume":"1","author":"Frost","year":"1994","journal-title":"Ann. Surg. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.dld.2013.04.013","article-title":"Small bowel adenocarcinoma: Epidemiology, risk factors, diagnosis and treatment","volume":"46","author":"Aparicio","year":"2014","journal-title":"Dig. Liver Dis."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.amjsurg.2009.05.037","article-title":"A single-institution experience with 491 cases of small bowel adenocarcinoma","volume":"199","author":"Halfdanarson","year":"2010","journal-title":"Am. J. Surg"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1245\/s10434-018-6369-x","article-title":"Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma: Multi-Institutional Experience","volume":"25","author":"Liu","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1634\/theoncologist.2012-0079","article-title":"Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy","volume":"17","author":"Tsushima","year":"2012","journal-title":"Oncologist"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1177\/000313481307900629","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma","volume":"79","author":"Sun","year":"2013","journal-title":"Am. Surg."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12885-015-1014-6","article-title":"Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience","volume":"15","author":"Khan","year":"2015","journal-title":"BMC Cancer"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1002\/cncr.25324","article-title":"Prognostic value of lymph node evaluation in small bowel adenocarcinoma: Analysis of the surveillance, epidemiology, and end results database","volume":"116","author":"Overman","year":"2010","journal-title":"Cancer"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/annonc\/mdq038","article-title":"Chemotherapy of advanced small-bowel adenocarcinoma: A multicenter AGEO study","volume":"21","author":"Zaanan","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10585-019-09955-4","article-title":"Pressurized intraperitoneal aerosol chemotherapy and its effect on gastric-cancer-derived peritoneal metastases: An overview","volume":"36","author":"Alberto","year":"2019","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"20180127","DOI":"10.1515\/pp-2018-0127","article-title":"The role of Pressurized IntraPeritoneal Aerosol Chemotherapy in the management of gastric cancer: A systematic review","volume":"4","author":"Garg","year":"2019","journal-title":"Pleura Peritoneum"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejso.2019.06.028","article-title":"Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"47","author":"Alyami","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: An analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1515\/pp-2016-0017","article-title":"Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and Doxorubicin administered as a pressurized aerosol: An open-label, Phase-2 study (PIPAC-GA2)","volume":"1","author":"Khomyakov","year":"2016","journal-title":"Pleura Peritoneum"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11605-015-2995-9","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis","volume":"20","author":"Nadiradze","year":"2015","journal-title":"J. Gastrointest. Surg."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.suronc.2020.05.006","article-title":"Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis","volume":"34","author":"Schena","year":"2020","journal-title":"Surg. Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12957-016-1008-0","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"14","author":"Girshally","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"ref_181","first-page":"1758835920940887","article-title":"Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma","volume":"12","author":"Sgarbura","year":"2020","journal-title":"Ther. Adv. Med. Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/2\/255\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:18:37Z","timestamp":1760120317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/2\/255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,28]]},"references-count":181,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["medicina59020255"],"URL":"https:\/\/doi.org\/10.3390\/medicina59020255","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,28]]}}}